Citations

Clear

75 citation(s) found for "Starlinger, P".

SILAC-Based Characterization of Plasma-Derived Extracellular Vesicles in Patients Undergoing Partial Hepatectomy
Resch, Ulrike , Hackl, Hubert , Brunnthaler, Laura, Probst, Joel, Jankoschek, Anna S, Aiad, Monika, Krueger, Marcus, Assinger, Alice , Pereyra, David , Assinger, Alice , Resch, Ulrike , Hackl, Hubert , Pereyra, David , Santol, Jonas , Nolte, Hendrik , Starlinger, Patrick

Mayo Clinic

International Journal of Molecular Sciences | October 4, 2024 | Volume: 25 | Issue: 19 | Pages: 10685

10.3390/ijms251910685 | PMID 39409015 Get It

Post-hepatectomy liver failure (PHLF) remains a significant risk for patients undergoing partial hepatectomy (PHx). Reliable prognostic markers and treatments to enhance liver regeneration are lacking. Plasma nanoparticles, including lipoproteins, exosomes, and extracellular vesicles (EVs), can reflect systemic and tissue-wide proteostasis and stress, potentially aiding liver regeneration. However, their role in PHLF is still unknown. Methods: Our study included nine patients with hepatocellular carcinoma (HCC) undergoing PHx: three patients with PHLF, three patients undergoing the associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) procedure, and three matched controls without complications after PHx. Patient plasma was collected before PHx as well as 1 and 5 days after. EVs were isolated by ultracentrifugation, and extracted proteins were subjected to quantitative mass spectrometry using a super-SILAC mix prepared from primary and cancer cell lines. Results: We identified 2625 and quantified 2570 proteins in the EVs of PHx patients. Among these, 53 proteins were significantly upregulated and 32 were downregulated in patients with PHLF compared to those without PHLF. Furthermore, 110 proteins were upregulated and 78 were downregulated in PHLF patients compared to those undergoing ALPPS. The EV proteomic signature in PHLF indicates significant disruptions in protein translation, proteostasis, and intracellular vesicle biogenesis, as well as alterations in proteins involved in extracellular matrix (ECM) remodelling and the metabolic and cell cycle pathways, already present before PHx. Conclusions: Longitudinal proteomic analysis of the EVs circulating in the plasma of human patients undergoing PHx uncovers proteomic signatures associated with PHLF, which reflect dying hepatocytes and endothelial cells and were already present before PHx.
Financial Toxicity of Long‐Term Survivors Who Underwent Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma
Muaddi, Hala , Zironda, Andrea , Zhang, Chi , Day, Courtney N. , Warner, Susanne G, Smoot, Rory L., Kendrick, Michael L. , Truty, Mark J. , Smoot, Rory L. , Smoot, Rory L , Starlinger, Patrick , Warner, Susanne G. , Cleary, Sean P. , Thiels, Cornelius A.

Mayo Clinic

Journal of Surgical Oncology | September 5, 2024 | Volume: 131 | Issue: 2 | Pages: 232-241

10.1002/jso.27871 | PMID 39233671 Get It

ABSTRACT Background Pancreatoduodenectomy (PD) for pancreatic cancer has a profound impact on patients' lives. However, the long‐term financial implications are poorly understood. Objective Assess the financial burden of long‐term survivors who underwent PD. Methods Patients who underwent PD between January 2011 and June 2019 were identified. To evaluate the long‐term financial burden, patients surviving ≥ 3 years post‐resection were prospectively surveyed using the Comprehensive Score for financial Toxicity (COST‐FACIT) and a customized institutionally developed questionnaire. A logistic regression model predicting high financial toxicity was used to identify predictive factors. Results Among 238 eligible patients, 137 (57.6%) responded. Responders had a median age of 66 (59–73) years, with 86.7% identifying as financial prosperous or comfortable. However, 33.3% experienced financial distress due to treatment costs, 27.3% demonstrated high financial toxicity on the COST‐FACIT survey, and 37.2% made sacrifices to afford treatment. Only 8.9% stated that the treatment costs influenced their decisions, and the majority (85.9%) did not discuss financial implications with healthcare providers. Multivariable analysis identified younger age as a risk factor for high financial toxicity. Conclusion One in three long‐term survivors experienced high financial toxicity, with younger age being a predictor. This emphasizes the need for efforts to provide comprehensive support and guidance to patients to navigate their oncological journey.
Systemic treatment post curative-intent intervention based on tumor-informed circulating tumor DNA result for oligometastatic colorectal cancer.
Siripoon, Teerada , O’Donnell, Conor, Naleid, Nikolas , Atwell, Thomas D. , Mitchell, Jessica L. , Hallemeier, Christopher L. , Mathis, Kellie L. , Shawki, Sherief , Starlinger, Patrick , Thiels, Cornelius A. , Warner, Susanne G. , Jethwa, Krishan R. , Hallemeier, Christopher Leigh , Mahipal, Amit , Jin, Zhao-Hui

Mayo Clinic

Journal of Clinical Oncology | August 12, 2024 | Volume: 42 | Issue: 23_suppl | Pages: 84-84

10.1200/jco.2024.42.23_suppl.84 Get It

84 Background: Local therapies potentially offer a curative approach for patients with oligometastatic colorectal cancer (CRC). The effectiveness of systemic chemotherapy following definitive local treatment in this setting is not well-defined. Tumor-informed circulating tumor DNA (ctDNA) might guide management strategies after curative-intent local treatment. Methods: This is a single institution retrospective study of patients with CRC who underwent curative-intent local therapy to an isolated site of metastatic disease and had post-intervention tumor-informed ctDNA (Signatera) testing. The study was approved by the institutional review board. Clinical characteristics, including ctDNA results, were collected and evaluated. Kaplan-Meier method and log-rank test were used to calculate and compare disease-free survival (DFS). Factors associated with DFS were analyzed using multivariate Cox proportional hazards model. Results: 45 patients were included with median age of 59 years, 62% being male, 91% white, and 53% with stage IV disease at diagnosis. 37% of the patients had RAS mutations, no patient had BRAF mutation, and 2.2% patient had mismatch repair deficient disease. Isolated liver metastases were present in 80% of patients, lung metastases in 11% and other sites in 9%. 44 patients received chemotherapy prior to definitive treatment, with a median treatment duration of 16 weeks. ctDNA tests were done prior to local therapy in 23 patients, with 14 cases (61%) testing positive. Definitive treatment included resection (58%), ablation (13%), radiotherapy (4%), and multimodality (25%). Post-definitive treatment chemotherapy was administered to 24 (53%) patients. ctDNA positivity following definitive therapy was observed in 10 patients (22%), which was associated with a poorer prognosis, with a median DFS of 5.3 months compared to 21.3 months for the ctDNA-negative group (p<0.001). These findings were confirmed on multivariate analysis. In patients who had negative ctDNA after definitive local treatment, median DFS was 14.9 months for those who received post-intervention chemotherapy versus 21.3 months for those without post-intervention chemotherapy (p=0.835). Conclusions: Patients with negative ctDNA results following definitive local therapy for isolated metastatic CRC have better prognosis. Post-intervention chemotherapy in this group of patients was not associated with improved DFS. ctDNA guided omission of post-intervention chemotherapy following curative-intent local treatment of oligometastatic CRC warrants further study. [Table: see text]
HMGB1-Mediated Cell Death—A Crucial Element in Post-Hepatectomy Liver Failure
Brunnthaler, Laura, Hammond, Thomas , Probst, Joel, Laferl, Valerie, Resch, Ulrike , Aiad, Monika, Janoschek, Anna Sofie, Gruenberger, Thomas , Hackl, Hubert , Starlinger, Patrick , Assinger, Alice , Hammond, Thomas G , Pereyra, David , Santol, Jonas , Resch, Ulrike , Gruenberger, Thomas , Hackl, Hubert , Starlinger, Patrick , Assinger, Alice , Pereyra, David

Mayo Clinic

International Journal of Molecular Sciences | July 2, 2024 | Volume: 25 | Issue: 13 | Pages: 7150

10.3390/ijms25137150 | PMID 39000266 Get It

Liver resection (LR) is the primary treatment for hepatic tumors, yet posthepatectomy liver failure (PHLF) remains a significant concern. While the precise etiology of PHLF remains elusive, dysregulated inflammatory processes are pivotal. Therefore, we explored the theragnostic potential of extracellular high-mobility-group-box protein 1 (HMGB1), a key damage-associated molecular pattern (DAMP) released by hepatocytes, in liver recovery post LR in patients and animal models. Plasma from 96 LR patients and liver tissues from a subset of 24 LR patients were analyzed for HMGB1 levels, and associations with PHLF and liver injury markers were assessed. In a murine LR model, the HMGB1 inhibitor glycyrrhizin, was administered to assess its impact on liver regeneration. Furthermore, plasma levels of keratin-18 (K18) and cleaved cytokeratin-18 (ccK18) were quantified to assess suitability as predictive biomarkers for PHLF. Patients experiencing PHLF exhibited elevated levels of intrahepatic and circulating HMGB1, correlating with markers of liver injury. In a murine LR model, inhibition of HMGB1 improved liver function, reduced steatosis, enhanced regeneration and decreased hepatic cell death. Elevated levels of hepatic cell death markers K18 and ccK18 were detected in patients with PHLF and correlations with levels of circulating HMGB1 was observed. Our study underscores the therapeutic and predictive potential of HMGB1 in PHLF mitigation. Elevated HMGB1, K18, and ccK18 levels correlate with patient outcomes, highlighting their predictive significance. Targeting HMGB1 enhances liver regeneration in murine LR models, emphasizing its role in potential intervention and prediction strategies for liver surgery.
Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal Cancer
O'Donnell, C. , Naleid, Nikolas , Siripoon, Teerada , Zablonski, Kevin , Storandt, Michael H. , Hallemeier, Christopher L. , Conces, Madison , Bajor, David L. , Starlinger, Patrick , Atwell, Thomas D. , Mitchell, Jessica L. , Mahipal, Amit , Jin, Zhaohui , O'Donnell, Conor D J , Zablonski, Kevin G , Starlinger, Patrick , Mitchell, Jessica , Mahipal, Amit , Jin, Zhaohui , Selfridge, Jennifer Eva , Hallemeier, Christopher Leigh , Jethwa, Krishan R. , Thiels, Cornelius A. , Warner, Susanne G.

Mayo Clinic

Cancers | July 1, 2024 | Volume: 16 | Issue: 13 | Pages: 2407

10.3390/cancers16132407 | PMID 39001469 Get It

(1) Background: Local therapies offer a potentially curative approach for patients with oligometastatic colorectal cancer (CRC). An evidence-based consensus recommendation for systemic therapy following definitive locoregional therapy is lacking. Tumor-informed circulating tumor DNA (ctDNA) might provide information to help guide management in this setting. (2) Methods: A multi-institutional retrospective study was conducted, including patients with CRC that underwent curative-intent locoregional therapy to an isolated site of metastatic disease, followed by tumor-informed ctDNA assessment. The Kaplan–Meier method and log-rank tests were used to compare disease-free survival based on ctDNA results. ctDNA test performance was compared to carcinoembryonic antigen (CEA) test results using McNemar’s test. (3) Results: Our study cohort consisted of 87 patients treated with locoregional interventions who underwent ctDNA testing. The initial ctDNA test post-intervention was positive in 28 patients and negative in 59 patients. The median follow-up time was 14.0 months. Detectable ctDNA post-intervention was significantly associated with early disease recurrence, with a median disease-free survival (DFS) of 6.63 months compared to 21.30 months in ctDNA-negative patients (p < 0.001). ctDNA detected a numerically higher proportion of recurrences than CEA (p < 0.097). Post-intervention systemic therapy was not associated with improved DFS (p = 0.745). (4) Conclusions: ctDNA results are prognostically important in oligometastatic CRC, and further prospective studies are urgently needed to define its role in guiding clinical decisions.
A Multicenter Exploration of the APRI/ALBI Score in Associating Liver Partition and Portal Vein Ligation for Staged hepatectomy’ (ALPPS)
Jonas, Jan Philipp , Sander, Sophia, Ardiles, Victoria , Wen, Z, Kysela, Marek , Rauchfuß, Falk , Ullmer, F, Wahba, Roger , Hahn, Oszkár , Fernández-Placencia, Ramiro , Campos, Ricardo Robles, Sparrelid, E., Petrowsky, Henrik , Oberkofler, Christian E. , Rössler, Fabian , Amann, Markus, Linecker, Michael , Müller, Philip C , Wen, Z, Romić, Ivan , Truant, Stéphanie , Reese, Tim , Guidetti, Cristiano , Santol, Jonas , Eshmuminov, Dilmurodjon , Amann, M, Ignatavičius, Povilas , Oberholzer, José , Starlinger, Patrick

Mayo Clinic

British Journal of Surgery | May 16, 2024 | Volume: 111 | Issue: Supplement_3 | Pages: No page available

10.1093/bjs/znae118.029 Get It

Abstract Background Perioperative morbidity and mortality remain a point of concern for the Associating Liver Partition and Portal Vein Ligation for Staged hepatectomy (ALPPS) procedure. Post-hepatectomy liver failure (PHLF) after the second step poses the most significant risk factor for futile outcome. Recovery of liver function after the first step of ALPPS is critically important to allow for sufficient liver function after this surgery. The APRI+ALBI score has been proposed as an easily assessable score to monitor liver function and its dynamic recovery. Aims We explored if the APRI+ALBI score was able to assess liver function recovery after the first step of ALPPS and allow for optimal timing of the 2nd step. Methods Based on the ALPPS registry, patients from 2012 to 2020 with available APRI+ALBI score were included. Postoperative outcomes (PHLF A – C, PHLF B + C, 90-day mortality and severe morbidity) were defined as per standard definitions. The APRI/ALBI score was monitored perioperatively. Results Overall, 464 patients from 16 international participating centers in the ALPPS registry were included. Clinically relevant PHLF (B + C) was observed in 7.5 % and of these 63 % of patients ultimately died due to liver failure. The APRI+ALBI score immediately increased after each surgical intervention and continuously decrease thereafter. Failure of the APRI+ALBI score to decrease until the 2nd step of ALPPS predicted PHLF B+C (p = 0.001; AUC 0.78). Particularly patients with high APRI+ALBI scores and short interstage intervals were at risk to develop PHLF B+C. Conclusion The APRI+ALBI score objectifies liver function recovery after the 1st step of ALPPS and failure to sufficiently decreased is associated with a higher risk for PHLF B+C. This might allow for optimized planning of the 2nd step of ALPPS to allow for sufficient liver function recovery to minimize the risk for PHLF B+C and associated futile outcome.
Characterization of Perioperative Serotonin in Patients Undergoing Orthotopic Liver Transplantation
Zott, Tobias , Kersten, Isabelle, Ortner, Max, Hüpper, Maria Noelle, Berlakovich, Gabriela , Silberhumer, Gerd R. , Berlakovich, Gabriela A , Silberhumer, Gerd R , Pereyra, David , Starlinger, Patrick

Mayo Clinic

Journal of Clinical Medicine | April 30, 2024 | Volume: 13 | Issue: 9 | Pages: 2640

10.3390/jcm13092640 | PMID 38731169 Get It

Background: Platelets were shown to be relevant for liver regeneration. In particular, platelet-stored serotonin (5-HT) proved to be a pro-regenerative factor in this process. The present study aimed to investigate the perioperative course of 5-HT and evaluate associations with patient and graft outcomes after othotopic liver transplantation (OLT). Methods: 5-HT was quantified in plasma and serum of 44 OLT recipients perioperatively, and in their respective donors. Olthoff’s criteria for early allograft dysfunction (EAD) were used to evaluate postoperative outcomes. Results: Patients with higher donor intra-platelet 5-HT per platelet (IP 5-HT PP) values had significantly lower postoperative transaminases (ASAT POD1: p = 0.006, ASAT POD5: p = 0.006, ASAT POD10: p = 0.02, ALAT POD1: p = 0.034, ALAT POD5: p = 0.017, ALAT POD10: p = 0.04). No significant differences were seen between postoperative 5-HT values and the occurrence of EAD. A tendency was measured that donor IP 5-HT PP is lower in donor-recipient pairs that developed EAD (p = 0.07). Conclusions: Donor IP 5-HT PP might be linked to the postoperative development of EAD after OLT, as higher donor levels are correlated with a more favorable postoperative course of transaminases. Further studies with larger cohorts are needed to validate these findings.
Tumor-Extrinsic Axl Expression Shapes an Inflammatory Microenvironment Independent of Tumor Cell Promoting Axl Signaling in Hepatocellular Carcinoma
Breitenecker, Kristina , Heiden, Denise, Demmer, Tobias, Weber, Gerhard, Primorac, Ana-Maria, Hedrich, Viola , Ortmayr, Gregor , Gruenberger, Thomas , Herndler‐Brandstetter, Dietmar , Barozzi, Iros , Mikulits, Wolfgang , Herndler-Brandstetter, Dietmar , Barozzi, Iros , Mikulits, Wolfgang , Gruenberger, Thomas , Weber, Gerhard, Starlinger, Patrick

Mayo Clinic

International Journal of Molecular Sciences | April 11, 2024 | Volume: 25 | Issue: 8 | Pages: 4202

10.3390/ijms25084202 | PMID 38673795 Get It

The activation of the receptor tyrosine kinase Axl by Gas6 is a major driver of tumorigenesis. Despite recent insights, tumor cell-intrinsic and -extrinsic Axl functions are poorly understood in hepatocellular carcinoma (HCC). Thus, we analyzed the cell-specific aspects of Axl in liver cancer cells and in the tumor microenvironment. We show that tumor-intrinsic Axl expression decreased the survival of mice and elevated the number of pulmonary metastases in a model of resection-based tumor recurrence. Axl expression increased the invasion of hepatospheres by the activation of Akt signaling and a partial epithelial-to-mesenchymal transition (EMT). However, the liver tumor burden of Axl+/+ mice induced by diethylnitrosamine plus carbon tetrachloride was reduced compared to systemic Axl−/− mice. Tumors of Axl+/+ mice were highly infiltrated with cytotoxic cells, suggesting a key immune-modulatory role of Axl. Interestingly, hepatocyte-specific Axl deficiency did not alter T cell infiltration, indicating that these changes are independent of tumor cell-intrinsic Axl. In this context, we observed an upregulation of multiple chemokines in Axl+/+ compared to Axl−/− tumors, correlating with HCC patient data. In line with this, Axl is associated with a cytotoxic immune signature in HCC patients. Together these data show that tumor-intrinsic Axl expression fosters progression, while tumor-extrinsic Axl expression shapes an inflammatory microenvironment.
Abstract 3784: Methylated DNA markers for detection of peritoneal metastasis in pancreatic cancer
Maheshwari, Kalika , Burger, Kelli N. , Delgado, Adriana, Streich, Heather M., Kendrick, Micheal L., Truty, Mark J. , Berger, Calise K. , Taylor, William R. , Mahoney, Douglas W. , Doering, Karen A. , Foote, Patrick H. , Cleary, Sean P. , Grotz, Travis E. , Smoot, Rory L. , Starlinger, Patrick , Thiels, Cornelius A. , Warner, Susanne G. , Kisiel, John B. , Majumder, Shounak

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 3784-3784

10.1158/1538-7445.am2024-3784 Get It

Abstract Introduction: Laparoscopy with peritoneal lavage enhances staging accuracy in patients with pancreatic ductal adenocarcinoma (PDAC). Occult intra-abdominal metastases are identified by staging laparoscopy in approximately 20% of patients with radiologically localized PDAC. Peritoneal fluid cytology has limited sensitivity in detecting occult intra-abdominal metastasis. Methylated DNA markers (MDMs) can accurately detect PDAC from tumor tissue, blood, and pancreatic secretions. This study aims to assess the feasibility of assaying MDMs in peritoneal lavage fluid obtained at the time of staging laparoscopy for patients with PDAC. Methods: Peritoneal lavage fluid (25-60 mL) obtained from patients with PDAC at the time of staging laparoscopy was centrifuged for 10 minutes at 1200 × g. The pellet was resuspended and aliquoted into 200µL tubes and frozen at -80°C. DNA extracted from one aliquot was assayed for mutant KRAS (G12A and G13D) and then bisulfite converted to measure 13 MDMs (GRIN2D, CD1D, ZNF781, FER1L4, RYR2, CLEC11A, AK055957, LRRC4, MAX.CHR5.4295, HOXA1, PRKCB, SHISA9, NTRK3) and a normalizing reference gene (B3GALT6) using quantitative methylation specific PCR. The association of KRAS and the average signal from the 13 MDMs (MDMscore) with intra-abdominal metastasis (Y/N) was assessed with the area under the receiver operator characteristic curve (AUC). Results: Among 48 PDAC patients, staging laparoscopy revealed intra-abdominal metastasis in 15 (31%). Of the 15 intra-abdominal metastases, 6 were found to have biopsy-confirmed intra-abdominal metastasis and positive peritoneal cytology, 4 were positive on peritoneal cytology alone, and 5 had biopsy-confirmed intra-abdominal metastasis alone. The sensitivity of the MDMscore for intra-abdominal metastasis was 87% (CI: 60-98%) at 90% (CI: 76-98%) specificity whereas the sensitivity for KRAS was 40% (CI: 16-68%) at 85% (CI: 68-95) specificity. The AUC for the MDMscore was 0.98 (CI: 0.94-1.00) compared to 0.62 (CI: 0.48-0.77) for that of KRAS (p&lt;0.0001). Conclusion: MDMs assayed from peritoneal lavage fluid collected during staging laparoscopy is a novel tool for accurate molecular staging of PDAC. These early results warrant further study in a larger cohort to assess impact on peritoneal staging and its clinical utility in the neoadjuvant treatment paradigm of PDAC. Citation Format: Kalika Maheshwari, Calise K. Berger, William R. Taylor, Douglas W. Mahoney, Kelli N. Burger, Adriana M. Delgado, Karen A. Doering, Heather M. Streich, Patrick H. Foote, Sean P. Cleary, Travis E. Grotz, Micheal L. Kendrick, Rory L. Smoot, Patrick P. Starlinger, Cornelius A. Thiels, Mark J. Truty, Susanne G. Warner, John B. Kisiel, Shounak Majumder. Methylated DNA markers for detection of peritoneal metastasis in pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3784.
A small molecule MST1/2 inhibitor accelerates murine liver regeneration with improved survival in models of steatohepatitis
Watkins, Ryan , Gamo, Ana M. , Choi, Seung Hyuk , Kumar, Manoj , Buckarma, EeeLN H. , McCabe, Chantal E. , Tomlinson, Jennifer L. , Pereya, David, Lupše, Blaž , Geravandi, Shirin , Werneburg, Nathan W., Zhu, Siying , Li, Sijia, Yu, Shan , Surakattula, Murali, Baguley, Tyler D., Ardestani, Amin , Roland, Jason, Petrassi, Mike, Rogers, Nikki Lynn, Chatterjee, Arnab K. , Tremblay, Matthew S. , Smoot, Rory L. , Buckarma, EeeLN , McCabe, Chantal , Tomlinson, Jennifer , Wang, Chen , Starlinger, Patrick , Li, Sijia , Ardestani, Amin , Maedler, Kathrin , Joseph, Sean , Rogers, Nikki , Gores, Gregory J. , Chatterjee, Arnab , Shen, Weijun , Smoot, Rory L , Wang, Chen , Starlinger, Patrick , Nguyen-Tran, Vân T. B. , Gores, Gregory J.

Mayo Clinic

PNAS Nexus | March 1, 2024 | Volume: 3 | Issue: 3 | Pages: No page available

10.1093/pnasnexus/pgae096 | PMID 38528952 Get It

Abstract Dysfunctional liver regeneration following surgical resection remains a major cause of postoperative mortality and has no therapeutic options. Without targeted therapies, the current treatment paradigm relies on supportive therapy until homeostasis can be achieved. Pharmacologic acceleration of regeneration represents an alternative therapeutic avenue. Therefore, we aimed to generate a small molecule inhibitor that could accelerate liver regeneration with an emphasis on diseased models, which represent a significant portion of patients who require surgical resection and are often not studied. Utilizing a clinically approved small molecule inhibitor as a parent compound, standard medicinal chemistry approaches were utilized to generate a small molecule inhibitor targeting serine/threonine kinase 4/3 (MST1/2) with reduced off-target effects. This compound, mCLC846, was then applied to preclinical models of murine partial hepatectomy, which included models of diet-induced metabolic dysfunction-associated steatohepatitis (MASH). mCLC846 demonstrated on target inhibition of MST1/2 and reduced epidermal growth factor receptor inhibition. The inhibitory effects resulted in restored pancreatic beta-cell function and survival under diabetogenic conditions. Liver-specific cell-line exposure resulted in Yes-associated protein activation. Oral delivery of mCLC846 perioperatively resulted in accelerated murine liver regeneration and improved survival in diet-induced MASH models. Bulk transcriptional analysis of regenerating liver remnants suggested that mCLC846 enhanced the normal regenerative pathways and induced them following liver resection. Overall, pharmacological acceleration of liver regeneration with mCLC846 was feasible, had an acceptable therapeutic index, and provided a survival benefit in models of diet-induced MASH.